You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The first application of the technology will be for noninvasive prenatal screening followed by cancer liquid biopsy testing.
Invitae said this week that it completed its acquisition of Singular Bio on June 19.
Senators said they'll narrow the draft bill containing changes to US patent law before submitting it to the Senate Judiciary Committee in July.
The acquisition will bring to Invitae single-molecule, cell-free DNA analysis technology and enable lower cost NIPS testing.
The testing programs are financially supported by the drugmakers, and will allow Invitae to provide free testing and genetic counseling for rare inherited retinal disease and primary immunodeficiencies.
Individual stocks in the GenomeWeb Index were mostly down in May, with 21 of the 30 stocks posting losses and nine stocks recording gains.
Invitae will perform genetic testing using a 58-gene panel and Horizon will provide financial support for the program aimed at improving diagnosis of the rare condition.
For the three months ended March 31, the firm generated $40.6 million in revenues, missing the consensus Wall Street estimate of $47.2 million.
Individuals identified as needing homozygous FH evaluation will receive confirmatory genetic testing from Invitae and genetic counseling from Genome Medical.
Research presented at ACMG by Invitae suggests that clinically actionable variants in cancer patients are missed by germline testing that is not done with expanded panels.
The Lancet has made changes to its peer-review process in response to its recent retraction of a COVID-19-related paper, Science reports.
The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.
A new initiative aims to move Australia's genome sequencing labs onto one system, the Sydney Morning Herald reports.
In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.